热点聚焦！董明珠：利他思想是制造业成功关键，勿以赚钱为先

董明珠：利他思想是制造业成功关键，勿以赚钱为先

北京时间2024年6月15日讯 - 在近日举行的第十七届全球光伏大会开幕式上，格力电器董事长兼总裁董明珠发表演讲，分享了她对制造业发展的独到见解。她强调，制造业的根本目的是为了满足社会需求，解决社会问题，因此企业不应该只想着赚钱，而应该把利他思想放在首位。

董明珠指出， 制造业是立国之本，强国之基。制造业的发展不仅能够为国家创造税收，提供就业岗位，更重要的是能够提升国家综合实力，改善人民生活质量。

然而， 当前一些制造企业只想着追求利润，忽视了社会责任，导致产品质量下降，售后服务差，严重损害了消费者权益。

董明珠呼吁， 制造企业应该树立利他思想，把社会责任放在首位，生产高质量的产品，提供优质的服务，为社会创造价值。

她表示， 只有这样，制造企业才能赢得消费者的信赖，获得长远发展。

董明珠的利他思想， 在业界引起了广泛共鸣。许多企业家表示，他们将学习董明珠的先进理念，把利他思想融入到企业经营中，为社会创造更大的价值。

以下是董明珠演讲中的部分金句：

• “制造业不要先考虑赚不赚钱，要利他。你的技术改变了别人，质量保证了别人，你的所有行为都利他，别人自然拥护你。”
• “一个企业如果没有社会责任感，那就不是一个合格的企业。”
• “我们制造业的目标，就是要让老百姓用得起、用得好、用得放心。”

董明珠的利他思想， 是对传统制造业理念的深刻反思。在新的时代背景下，制造企业只有树立利他思想，才能赢得消费者的信赖，获得长远发展。

未来展望：

我们相信，随着越来越多的企业家认同并践行利他思想，中国制造业一定会迎来更加美好的未来。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.